Abbott Laboratories (ABT) Stock Forecast & Price Target $88.61 -0.21 (-0.24%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 26 Analyst RatingsSell0Hold5Buy21 Based on 26 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 5 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for ABT. Consensus Price Target $119.4334.79% Upside According to the 26 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $119.43. The highest price target for ABT is $143.00, while the lowest price target for ABT is $92.00. The average price target represents a forecasted upside of 34.79% from the current price of $88.61. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ABT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABT Analyst Ratings Over TimeTypeCurrent Forecast5/20/25 to 5/20/261 Month Ago4/20/25 to 4/20/263 Months Ago2/19/25 to 2/19/261 Year Ago5/20/24 to 5/20/25Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)Buy19 Buy rating(s)19 Buy rating(s)16 Buy rating(s)13 Buy rating(s)Hold5 Hold rating(s)4 Hold rating(s)4 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$119.43$121.57$137.05$143.31Forecasted Upside34.79% Upside26.56% Upside22.13% Upside6.02% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ABT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ABT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Abbott Laboratories Stock vs. The CompetitionTypeAbbott LaboratoriesMedical CompaniesBroader MarketConsensus Rating Score 2.88 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside34.48% Upside1,742.55% Upside17.78% UpsideNews Sentiment RatingPositive NewsSee Recent ABT NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails4/27/2026 BTIG Research2 of 5 starsMarie Thibault2 of 5 starsReiterated RatingBuy$131.00+43.71%4/24/2026 Weiss RatingsNot Rated DowngradeHold (C) ➝ Hold (C-)4/22/2026 Daiwa Securities Group3 of 5 stars DowngradeOutperform ➝ Neutral$92.00-0.89%4/21/2026 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$140.00 ➝ $125.00+30.13%4/21/2026 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetMarket Perform$119.00 ➝ $106.00+10.35%4/20/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$158.00 ➝ $135.00+40.54%4/20/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt MiksicSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$144.00 ➝ $143.00+47.59%4/17/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingShagun SinghSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOutperform$135.00 ➝ $130.00+36.73%4/17/2026 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOutperform$125.00 ➝ $110.00+15.70%4/17/2026 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOutperform$134.00 ➝ $120.00+26.22% Get the Latest News and Ratings for ABT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter. 4/17/2026 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOutperform$130.00 ➝ $115.00+20.96%4/17/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetNeutral$125.00 ➝ $115.00+20.96%4/17/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOverweight$122.00 ➝ $109.00+14.65%4/17/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOverweight$123.00 ➝ $110.00+15.70%4/17/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAdam MaederSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$135.00 ➝ $115.00+20.96%4/17/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$145.00 ➝ $135.00+41.99%4/17/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$136.00 ➝ $108.00+13.59%4/17/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$137.00 ➝ $115.00+20.96%4/17/2026 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSuraj KaliaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOutperform$132.00 ➝ $115.00+20.96%4/17/2026 BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBruce D.Subscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$145.00 ➝ $120.00+26.22%4/17/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRick WiseSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$145.00 ➝ $120.00+26.22%4/17/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTravis SteedSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$150.00 ➝ $120.00+26.22%4/8/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid RomanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$140.00 ➝ $121.00+18.90%1/29/2026 Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Strong-Buy11/20/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy7/15/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid LewisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$127.00 ➝ $137.00+3.75%7/30/2024 Edward JonesSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeBuy ➝ HoldAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:56 PM ET. Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 15, 2026. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com. Abbott Laboratories Bull Case Here are some ways that investors could benefit from investing in Abbott Laboratories: The current stock price is around $119, reflecting a moderate buy consensus among analysts, which may indicate potential for growth. Abbott Laboratories has a strong dividend yield of 3.0%, providing investors with a steady income stream, which is appealing in a low-interest-rate environment. Recent institutional investments, including significant acquisitions by PFA Pension and Danica Pension, suggest confidence in Abbott Laboratories' future performance. The company has a diverse portfolio across diagnostics, medical devices, and nutritionals, which can help mitigate risks associated with market fluctuations in any single sector. Abbott Laboratories has a solid track record of innovation, continuously developing new products that address a wide range of health conditions, enhancing its competitive edge. Abbott Laboratories Bear Case Investors should be bearish about investing in Abbott Laboratories for these reasons: Recent target price reductions by analysts, including a drop from $144 to $143 by Barclays, may indicate a cautious outlook on the stock's short-term performance. The company's dividend payout ratio is currently at 70.59%, which, while sustainable, may limit the funds available for reinvestment into growth opportunities. Insider selling activity, with 3,055 shares sold recently, could raise concerns about the confidence of company executives in the stock's future performance. Market volatility and economic uncertainties could impact Abbott Laboratories' sales, particularly in its consumer health and nutrition segments. Increased competition in the healthcare sector may pressure Abbott Laboratories' market share and profit margins, affecting long-term growth potential. ABT Forecast - Frequently Asked Questions What is Abbott Laboratories' forecast for 2026? According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $119.43, with a high forecast of $143.00 and a low forecast of $92.00. Should I buy or sell Abbott Laboratories stock right now? 26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 5 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABT shares. Does Abbott Laboratories's stock price have much upside? According to analysts, Abbott Laboratories's stock has a predicted upside of 34.79% based on their 12-month stock forecasts. Has Abbott Laboratories been downgraded by Wall Street analysts recently? Over the previous 90 days, Abbott Laboratories's stock had 2 downgrades by analysts. What analysts cover Abbott Laboratories? Abbott Laboratories has been rated by research analysts at Argus, Bank of America, Barclays, Benchmark, BTIG Research, Citigroup, Daiwa Securities Group, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Oppenheimer, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Abbott Laboratories more than its competitors? Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies. Stock Forecasts and Research Tools Related Companies DXCM Stock Forecast ISRG Stock Forecast TSLA Stock Forecast ABBV Stock Forecast BSX Stock Forecast ELV Stock Forecast ITGR Stock Forecast JNJ Stock Forecast MDT Stock Forecast TMO Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Abbott Laboratories RecommendationsBTIG ResearchWeiss RatingsDaiwa Securities GroupLeerink PartnersArgusBarclaysUBS GroupEvercoreRaymond James FinancialRoyal Bank Of CanadaSanford C. BernsteinCitigroupJefferies Financial GroupMizuhoWells Fargo & Company This page (NYSE:ABT) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
